News

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

The NDA is supported by data from the phase 3 TRIUMpH clinical program and seeks approval for heartburn in NERD, healing of erosive esophagitis, and maintenance of healing.

In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.

Repeat monthly dosing of sustained-release lidocaine ST-01 met primary and secondary endpoints in phase 2 trial, delivering durable pain relief in men with chronic scrotal pain.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.

In her interview, Melinda Gooderham, MD, highlights the impact of recent topline findings on zasocitinib, a once-daily pill for adults with psoriasis.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and other regulatory updates, in this week’s essential news roundup.

Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.

In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).

An 18-month study of children with up to 5 nut allergies found that a 30-mg per-nut maintenance dose significantly improved tolerated doses without serious adverse events.

A prospective study reports an association between diabetes mellitus and anuria with high post-void residual post-transplantation.

Wingate reviews new Crohn’s and Colitis Foundation data on insurance barriers faced by young adults with IBD and offers practical insights for overcoming these challenges.

Topline 52 week results show durable growth without compromising safety or tolerability, as well as benefits beyond linear growth with combination treatment.

Rubin discusses the recently released best practice recommendations for HypoPT treatment, explaining how clinicians can help turn this dangerous disease around.

According to new research, investigators project a rising chronic kidney disease burden in young adults and a declining incidence in children by 2050.

In this post hoc analysis, investigators used phase 3 data on vunakizumab to investigate the impact of early response on long-term efficacy in those with psoriasis.

A study found tahini was associated with lower reaction thresholds and higher anaphylaxis rates than whole seeds, suggesting it may better reflect true sesame allergy risk.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

December 2025 saw new data on asthma therapies and new insights from experts on continuing trends in the field.

A retrospective cohort analysis reports data on a two-sided relationship between depression diagnosis and chronic kidney disease progression.

The document outlines 14 best-practice advice statements for diagnosing and managing refractory constipation, with an emphasis on surgical intervention.

A study links caregiver beliefs, mental health challenges, multiple allergens, and prior anaphylaxis to worse food allergy–related quality of life in pediatric patients.

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Rubin discusses an analysis of Ascendis’s program for patients who had received PTH treatment but weren’t eligible for clinical trials of palopegteriparatide.